8.22  0 (0%)		12-31 19:00
Open: 8.24 High: 8.25 Volume: 3,151,400		Pre. Close: 8.22 Low: 8.18 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	9.63	1-year :	11.25
Resists	First :	8.25	Second :	9.63
Pivot price	8.22
Supports	First :	8.2	Second :	8.18
MAs	MA(5) :	8.22	MA(20) :	8.22
	MA(100) :	7.42	MA(250) :	6.04
MACD	MACD :	0.01	Signal :	0.01
%K %D	K(14,3) :	57.14	D(3) :	57.14
RSI	RSI(14): 73.52
52-week	High :	8.25	Low :	4.01

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Wed, 24 Nov 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals - GlobeNewswire

Mon, 11 Oct 2021
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio - GlobeNewswire

Mon, 11 Oct 2021
ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News - InvestorPlace

Mon, 11 Oct 2021
Supernus bolsters Parkinson's portfolio with $400 mln deal for Adamas Pharma - Reuters

Thu, 22 Jul 2021
Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101 - Business Wire

Fri, 09 Jul 2021
Adamas Announces New Employment Inducement Grant - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Shares Out	46 (M)
Shares Float	31 (M)
Held by Insiders	1.7 (%)
Held by Institutions	80.3 (%)
Shares Short	1,600 (K)
Shares Short P.Month	2,510 (K)

EPS	-1.61
EPS Est Next Qtrly	-1.17
EPS Est This Year	-3.77
EPS Est Next Year	-3.43
Book Value (p.s.)	-0.1
Profit Margin	-66.82 %
Operating Margin	-45.14 %
Return on Assets (ttm)	-16.4 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	16.89 %
Gross Profit (p.s.)	1.58
Sales Per Share	1.8
EBITDA (p.s.)	-0.81
Qtrly Earnings Growth	0 %
Operating Cash Flow	-51 (M)
Levered Free Cash Flow	-29 (M)

PE Ratio	-5.14
PEG Ratio	0
Price to Book value	-91.34
Price to Sales	4.55
Price to Cash Flow	-0.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.